Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control

  • 427 Accesses

  • 18 Citations

Abstract

Objective

Recently, we reported that alpha 1A-adrenoceptor (AR) is the main participant in phenylephrine-induced human ureteral contraction. We therefore decided to carry out a prospective randomized study to evaluate the effects of silodosin, a selective alpha 1A AR antagonist, as a medical expulsive therapy (MET) for distal ureteral stones.

Methods

A total of 112 male patients, who were referred to our department for the management of symptomatic unilateral distal ureteral calculi of less than 10 mm, were randomly divided into two groups: group A (56 patients) who were instructed to drink 2 L of water daily and group B (56 patients) who received the same instruction and were also given silodosin (8 mg/daily) for a maximum of 4 weeks. Expulsion rate, expulsion time and need for analgesics were examined.

Results

The expulsion rate was 55.3 % (56 patients) for group A and 72.7 % (55 patients) for group B (P = 0.106). The expulsion rate for <5 mm was 92.9 % (28 patients) for group A and 69.2 % (26 patients) for group B (P = 0.053). The expulsion rate for ≥5 mm was 17.9 % (28 patients) for group A and 75.9 % (29 patients) for group B (P = 0.001). The expulsion time was 13.40 ± 5.90 and 9.29 ± 5.91 days, respectively (P = 0.012). Analgesics were required 1.5 ± 3.1 and 0.3 ± 0.9 times, respectively (P = 0.382). Stone size in expulsion cases was 3.64 ± 1.25 and 5.23 ± 2.32 mm, respectively (P = 0.003).

Conclusions

Stone size has been identified as an important predictive factor for stone expulsion. Therefore, it is important that administration of silodosin can facilitate expulsion of 1.5 mm or larger distal ureteral stones, as compared to control. We believe that silodosin might have potential as a MET for distal ureteral stones.

This is a preview of subscription content, log in to check access.

Fig. 1

Abbreviations

AR:

Adrenoceptor

MET:

Medical expulsive therapy

SWL:

Shock wave lithotripsy

References

  1. 1.

    Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States. Kidney Int 63:1817–1823

  2. 2.

    Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758–767

  3. 3.

    Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, Sarica K, Türk C, Wolf JS Jr (2007) 2007 Guideline for the management of ureteral calculi. J Urol 178:2418–2434

  4. 4.

    Borghi L, Meschi T, Amato F, Novarini A, Giannini A, Quarantelli C, Mineo F (1994) Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo- controlled study. J Urol 152:1095–1098

  5. 5.

    Porpiglia F, Destefanis P, Fiori C, Fontana D (2000) Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 56:579–582

  6. 6.

    Cervenakov I, Fillo J, Mardiak J, Kopecny M, Smirala J, Lepies P (2002) Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker-tamsulosin. Int Urol Nephrol 34:25–29

  7. 7.

    Dellabella M, Milanese G, Muzzonigro G (2003) Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 170:2202–2205

  8. 8.

    Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, Hollenbeck BK (2006) Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 368:1171–1179

  9. 9.

    Parsons JK, Hergan LA, Sakamoto K, Lakin C (2007) Efficacy of alpha blockers for the treatment of ureteral stones. J Urol 177:983–987

  10. 10.

    Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K (2011) Characterization of α (1)-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology 77(762):e13–e17

  11. 11.

    Tomiyama Y, Kobayashi K, Tadachi M (2007) Expressions and mechanical functions of alpha 1 adrenoceptor subtypes in hamster ureter. Eur J Pharmacol 573:201–205

  12. 12.

    Tomiyama Y, Murakami M, Akiyama K (2002) Modification of ureteral motility and promotion of urine flow around an intra-ureteral obstruction by CL-316423, phenylephrine, and furosemide in dogs. Neurourol Urodyn 21:251–257

  13. 13.

    Morita T, Wada I, Suzuki T (1987) Characterization of alpha adrenoceptor subtypes involved in regulation of ureteral fluid transport. Tohoku J Exp Med 152:111–118

  14. 14.

    Itoh Y, Kojima Y, Yasui T, Okada A, Tozawa K, Kohri K (2007) Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 14:749–753

  15. 15.

    Karim B, Margaret P, Yair L (2008) Cost-effectiveness of medical expulsive therapy using alpha blockers for the treatment of distal ureteral stones. Eur Urol 53:411–419

  16. 16.

    Kobayashi S, Tomiyama Y, Hoyano Y, Yamazaki Y, Kusama H, Itoh Y, Kubota Y, Kohri K (2009) Gene expressions and mechanical functions of alpha 1 adrenoceptor subtypes in mouse ureter. World J Urol 27:775–780

  17. 17.

    Türk C, Knoll T, Petrik A, Sarica K, Straub M, Seitz C (2011) Guidelines on urolithiasis. European association of urology, Arnhem, pp 21–23

  18. 18.

    Miller OF, Kane CJ (1999) Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 162:688–690

Download references

Conflict of interest

No conflict of interest.

Author information

Correspondence to Yasunori Itoh.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Itoh, Y., Okada, A., Yasui, T. et al. Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control. Int Urol Nephrol 45, 675–678 (2013). https://doi.org/10.1007/s11255-013-0429-8

Download citation

Keywords

  • Urolithiasis
  • Selective alpha 1A-adrenoceptor antagonist
  • Medical expulsive therapy
  • Distal ureteral stone
  • Silodosin
  • Stone size